BioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy Trial

BioXcel Therapeutics Inc (NASDAQ: BTAI) announced overall survival (OS) data from its Phase 2 trial of BXCL701 in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients with metastatic castration-resistant prostate cancer of adenocarcinoma phenotype, the most common form of the disease

As of a September 6, 2023 data cutoff, evaluable patients with adenocarcinoma (n=29) showed a median OS ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

disclaimer_press_release